Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BRIVARACETAM | 50MG | TABLET | Resolved | 2025-01-09 | 2025-02-14 | 247388 |
| APO-BRIVARACETAM | 75MG | TABLET | Resolved | 2025-01-23 | 2025-02-14 | 248486 |
| APO-BROMAZEPAM | 3MG | TABLET | Resolved | 2024-10-18 | 2024-10-25 | 240699 |
| APO-BROMAZEPAM | 1.5MG | TABLET | Resolved | 2018-05-15 | 2018-08-28 | 49484 |
| APO-BROMFENAC | 0.07% | SOLUTION | Resolved | 2024-01-19 | 2024-03-22 | 216678 |
| APO-BROMFENAC | 0.07% | SOLUTION | Resolved | 2023-12-01 | 2024-01-05 | 212389 |
| APO-BUSPIRONE | 10MG | TABLET | Resolved | 2023-02-09 | 2023-05-12 | 184072 |
| APO-BUSPIRONE | 10MG | TABLET | Resolved | 2022-09-23 | 2022-10-21 | 170109 |
| APO-BUSPIRONE | 10MG | TABLET | Actual shortage | 2024-01-26 | 2024-02-02 | 217484 |
| APO-BUSPIRONE | 10MG | TABLET | Resolved | 2017-10-23 | 2017-11-20 | 26564 |
| APO-BUSPIRONE | 10MG | TABLET | Resolved | 2017-05-24 | 2017-06-27 | 11056 |
| APO-BUSPIRONE | 10MG | TABLET | Resolved | 2021-01-29 | 2021-03-24 | 132706 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2023-12-15 | 2023-12-22 | 213587 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2024-01-12 | 2024-10-10 | 215982 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2018-02-26 | 2021-03-02 | 41136 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2018-01-03 | 2020-02-25 | 34838 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18517 |
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18520 |
| APO-CANDESARTAN | Resolved | 2020-03-09 | 2020-05-04 | 108228 | ||
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2020-04-13 | 2020-10-19 | 111895 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |